ASX ANNOUNCEMENT **27 May 2026**

Expected Timing of Clinical Trial Results

Melbourne, Australia; 27 May 2026: Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, provides an update on the expected timing of results from two major efficacy trials with its Cymerus™ iPSC[1]-derived MSC[2] products.

Phase 3 Osteoarthritis Trial (CYP-004)

The Australian Phase 3 SCUlpTOR[3] trial of CYP-004 in patients with osteoarthritis of the knee is being conducted by the University of Sydney (USYD) and funded through an NHMRC[4] project grant. CYP-004 is Cynata's Cymerus™ iPSC-derived MSC product candidate for intra-articular injection (injection into a joint), designed to calm joint inflammation, relieve pain and protect cartilage. The trial enrolled a total of 321 patients, who were randomised to receive either CYP-004 or placebo, with co-primary endpoints assessing change in pain and cartilage thickness.

USYD has informed the Company that the study database has been successfully locked, the process of data analysis is now progressing well, and results are expected during June 2026.

Phase 2 acute Graft versus Host Disease Trial (CYP-001)

The multi-national Phase 2 trial of CYP-001 in adults with acute graft versus host disease (aGvHD) is being conducted by Cynata. CYP-001 is Cynata's Cymerus™ iPSC-derived MSC product for intravenous use, designed to modulate the immune system and improve both response rates and survival outcomes in aGvHD. A total of 65 participants were enrolled across clinical centres in Australia, the USA and Europe, randomised to receive either steroids plus CYP-001 or steroids plus placebo. The primary endpoint is Overall Response Rate at Day 28.

Database lock for this trial is expected to occur in early June 2026, with results anticipated in late June or early July.

Dr Kilian Kelly, Cynata's Chief Executive Officer and Managing Director, said:

"A great deal of progress has been made with the process of data monitoring, cleaning, quality control and analysis for these two hugely important trials. Each of these readouts in its own right has the potential to be transformative for the Company, and to set us on course to improve the lives of many patients with these serious diseases. We look forward to sharing the results with our investors as soon as possible."

-ENDS-

Authorised for release by Dr Kilian Kelly, CEO & Managing Director

CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, investors@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods.

Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of

CYP-001 in patients undergoing kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

---

[1] iPSC = induced pluripotent stem cell.
[2] MSC = mesenchymal stem (or stromal) cell.
[3] SCUlpTOR = Stem Cells as a symptom- and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis
[4] NHMRC -= National Health and Medical Research Council